• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Norepinephrine dose reporting: are we looking at different sides of the same coin?

作者信息

Ibarra-Estrada Miguel, Kattan Eduardo, Jung Christian

机构信息

Unidad de Terapia Intensiva, Hospital Civil Fray Antonio Alcalde, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.

Departamento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Intensive Care Med. 2024 Jul;50(7):1181-1182. doi: 10.1007/s00134-024-07487-4. Epub 2024 May 22.

DOI:10.1007/s00134-024-07487-4
PMID:38775863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11245408/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d631/11245408/b897e442f71e/134_2024_7487_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d631/11245408/b897e442f71e/134_2024_7487_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d631/11245408/b897e442f71e/134_2024_7487_Fig1_HTML.jpg

相似文献

1
Norepinephrine dose reporting: are we looking at different sides of the same coin?去甲肾上腺素剂量报告：我们看到的是同一枚硬币的不同面吗？
Intensive Care Med. 2024 Jul;50(7):1181-1182. doi: 10.1007/s00134-024-07487-4. Epub 2024 May 22.
2
Norepinephrine administration in septic shock: how much is enough?脓毒性休克中去甲肾上腺素的使用：多少剂量才足够？
Crit Care Med. 2002 Jun;30(6):1398-9. doi: 10.1097/00003246-200206000-00055.
3
Essential lessons in cardiogenic shock: epinephrine versus norepinephrine/dobutamine.心源性休克的重要经验教训：肾上腺素与去甲肾上腺素/多巴酚丁胺的对比
Crit Care Med. 2011 Mar;39(3):583-4. doi: 10.1097/CCM.0b013e318208e381.
4
Comment on "A comparison of epinephrine and norepinephrine in critically Ill patients".关于“危重症患者肾上腺素与去甲肾上腺素的比较”的评论
Intensive Care Med. 2009 Jul;35(7):1310; author reply 1311. doi: 10.1007/s00134-009-1492-6. Epub 2009 Apr 15.
5
Noradrenaline as a vasoactive agent in septic shock.去甲肾上腺素作为脓毒性休克中的血管活性药物。
Intensive Care Med. 2000 May;26(5):648. doi: 10.1007/s001340051222.
6
Arginine vasopressin in vasodilatory shock.
Circulation. 2003 Nov 11;108(19):e141; author reply e141.
7
Arginine vasopressin in advanced vasodilatory shock.精氨酸加压素在晚期血管舒张性休克中的应用
Circulation. 2003 Nov 11;108(19):e142; author reply e142. doi: 10.1161/01.CIR.0000099845.53469.EA.
8
[Possible induction to mistake in the dilution of noradrenaline].[去甲肾上腺素稀释过程中可能导致错误的诱因]
Farm Hosp. 2013 Nov-Dec;37(6):558-9. doi: 10.7399/FH.2013.37.6.1064.
9
Norepinephrine or just more epinephrine: Which is the best vasopressor for post-arrest shock?去甲肾上腺素还是更多的肾上腺素：哪种是心脏骤停后休克的最佳血管加压药？
Resuscitation. 2024 May;198:110215. doi: 10.1016/j.resuscitation.2024.110215. Epub 2024 Apr 10.
10
Vasopressor infusion during off-pump coronary artery bypass graft surgery.非体外循环冠状动脉旁路移植手术期间的血管加压药输注
J Cardiothorac Vasc Anesth. 2000 Dec;14(6):763-4. doi: 10.1053/s1053-0770(00)70033-4.

引用本文的文献

1
Norepinephrine pharmacolexicology: a chronological review of dose reporting and the implications of salt formulations.去甲肾上腺素药理学：剂量报告的时间顺序回顾及盐制剂的影响
Intensive Care Med. 2025 Sep;51(9):1664-1673. doi: 10.1007/s00134-025-08053-2. Epub 2025 Jul 29.
2
The impact of norepinephrine dose reporting heterogeneity on mortality prediction in septic shock patients.去甲肾上腺素剂量报告异质性对脓毒性休克患者死亡率预测的影响。
Crit Care. 2024 Jul 3;28(1):216. doi: 10.1186/s13054-024-05011-0.
3
Norepinephrine salt formulations are not a matter of pharmacologic potency.

本文引用的文献

1
Norepinephrine salt formulations are not a matter of pharmacologic potency.去甲肾上腺素盐制剂并非药效问题。
Intensive Care Med. 2024 Jul;50(7):1179-1180. doi: 10.1007/s00134-024-07451-2. Epub 2024 May 2.
2
Position Paper on the Reporting of Norepinephrine Formulations in Critical Care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force.关于重症监护中去甲肾上腺素制剂报告的立场文件：来自重症监护医学学会和欧洲危重病医学学会联合工作组。
Crit Care Med. 2024 Apr 1;52(4):521-530. doi: 10.1097/CCM.0000000000006176. Epub 2024 Jan 19.
3
The Relationship Between Norepinephrine Equivalent Dose of Vasopressors Within 24 Hours From the Onset of Septic Shock and In-Hospital Mortality Rate.
去甲肾上腺素盐制剂并非药效问题。
Intensive Care Med. 2024 Jul;50(7):1179-1180. doi: 10.1007/s00134-024-07451-2. Epub 2024 May 2.
4
Norepinephrine dose and concentration reporting: the devil is in the details.去甲肾上腺素剂量与浓度报告：细节决定成败。
Intensive Care Med. 2024 Jun;50(6):1008-1009. doi: 10.1007/s00134-024-07446-z. Epub 2024 Apr 24.
5
Norepinephrine dose and concentration reporting: a closer look at the fine print.去甲肾上腺素剂量与浓度报告：细究细则
Intensive Care Med. 2024 Jun;50(6):1006-1007. doi: 10.1007/s00134-024-07425-4. Epub 2024 Apr 10.
感染性休克发病后24小时内血管升压药去甲肾上腺素等效剂量与住院死亡率的关系。
Chest. 2023 Jan;163(1):148-151. doi: 10.1016/j.chest.2022.07.018. Epub 2022 Jul 31.
4
Hemodynamic phenotype-based, capillary refill time-targeted resuscitation in early septic shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial study protocol.基于血流动力学表型、以毛细血管再充盈时间为目标的早期脓毒性休克复苏：ANDROMEDA-SHOCK-2 随机临床试验研究方案。
Rev Bras Ter Intensiva. 2022 Jan-Mar;34(1):96-106. doi: 10.5935/0103-507X.20220004-pt.
5
Defining and characterizing drug/compound function.定义和描述药物/化合物的功能。
Biochem Pharmacol. 2014 Jan 1;87(1):40-63. doi: 10.1016/j.bcp.2013.07.033. Epub 2013 Aug 15.